How likely is knee OA after ACL reconstruction?

Half of all patients who undergo ACL reconstruction will develop signs of knee osteoarthritis within 10 to 14 years of surgery — a figure that climbs to 73% by the time two decades have passed, with roughly 1 in 8 reaching severe OA at that stage. These numbers come from a systematic review and meta-analysis tracking outcomes at a mean follow-up of 22.7 years, and they represent the clearest long-term picture the evidence currently offers.

The risk is not evenly shared between the two knees. The reconstructed side carries approximately 2.8 times the OA risk of the uninjured contralateral limb — a disparity that persists regardless of how technically successful the reconstruction was.

Not all risk factors are fixed at the point of injury, which is why they matter clinically. The strongest modifiable factor is concomitant damage to the meniscus or articular cartilage at the time of the ACL tear; patients who sustain these combined injuries face a substantially higher OA burden than those with an isolated ligament rupture. Non-modifiable factors — male sex, older age at the time of surgery, and delayed reconstruction — raise baseline risk but cannot be changed once surgery has taken place.

Important context sits alongside these figures: conversion to total knee arthroplasty affects roughly 2% of patients who have had ACL reconstruction — far lower than the rate seen after non-operative ACL management. Most people, in other words, do not reach end-stage joint failure. That does not diminish the risk so much as it shifts the focus: recognising early structural change, and understanding what drives it, is what creates the opportunity to act before OA becomes established.

What changes inside the joint after reconstruction

Four overlapping processes explain why an apparently successful reconstruction can still set the joint on a path towards osteoarthritis.

1. A persistent biochemical disturbance

From the moment of injury, the joint fluid shifts into an inflammatory state — elevated cytokines, degradation enzymes, and markers of collagen breakdown have been measured in patients for up to five years after ACL rupture. The joint never fully quiets back to its pre-injury chemistry; it stays in a low-grade repair mode that slowly wears on cartilage long after the ligament itself has healed.

2. Medial meniscal extrusion

The medial meniscus acts as a shock absorber by sitting precisely within the joint space. After ACL reconstruction, the meniscus on the injured side tends to shift outward — a change known as medial meniscal extrusion — to a measurably greater degree than on the uninjured knee, and this displacement continues to worsen at three years post-surgery. When the meniscus migrates out of position, the cartilage of the posterior medial femoral condyle bears load it was not designed to carry, and specific MRI signals (T1ρ and T2 sequences that flag early cartilage water content changes) reflect this degeneration.

3. Altered patellofemoral loading

Biomechanical studies show that how load is distributed across the kneecap joint changes after reconstruction. Reduced patellofemoral contact force during dynamic tasks at one year post-surgery predicts both early cartilage lesions at that stage and progressive patellofemoral OA by five years — a clear mechanical pathway from altered movement patterns to structural damage.

4. Subchondral bone remodelling

Beneath the cartilage surface, bone shape begins to change early. Data from the KANON trial link early OA symptoms after ACL injury to detectable bone shape alterations that precede any change visible on plain X-ray — meaning a normal radiograph does not rule out ongoing joint remodelling.

Critically, all four processes leave measurable traces. Sensitive imaging and cartilage biomarkers can detect them before symptoms become disabling — which is the basis for early recognition.

Picking up early OA changes before symptoms worsen

Symptoms and structural change do not always advance in step. A patient can have significant MRI-visible cartilage matrix disruption with relatively mild discomfort; another may report substantial pain with modest structural findings. This mismatch matters clinically: waiting for pain to worsen before investigating risks missing the period during which early intervention — including the injection-based options discussed later — may be most effective.

Plain radiographs are a routine starting point but a poor monitoring tool in this population. Joint space narrowing visible on X-ray indicates established cartilage loss, not early disease. Bone shape alterations linked to early OA symptoms — demonstrated in the KANON trial — can occur before any radiographic change is apparent, meaning a normal X-ray does not exclude meaningful remodelling.

MRI offers considerably more granularity. T1ρ and T2 mapping sequences detect changes in cartilage water content and matrix integrity before structural loss appears on standard sequences. Medial meniscal extrusion, measurable on MRI, correlates directly with loading stress on the posterior medial femoral condyle — a quantifiable signal of cartilage breakdown in progress. Patellofemoral assessment, through functional evaluation and targeted imaging, adds a further layer where indicated.

No single imaging protocol currently covers all relevant domains in a standardised way. The choice of sequences is guided by the clinical picture, symptom pattern, and time elapsed since reconstruction. The practical value of recognising these changes early is straightforward: it creates access to the structured treatment window that exists between symptomatic OA and the point at which arthroplasty becomes necessary.

Injection options during the pre-replacement window

For patients in the symptomatic but pre-arthroplasty phase, intra-articular injection is a practical way to manage pain and maintain function while longer-term options are weighed. The choice between agents is clinical rather than formulaic — OA stage, symptom pattern, overall joint trajectory, and distance from possible arthroplasty all influence what is likely to be recommended.

Corticosteroid acts quickly, often within days, and provides clinically meaningful relief in early-to-moderate post-traumatic knee OA. The limitation is duration: relief typically fades within two to three months. Repeated use at short intervals — generally taken to mean more than two or three injections per year into the same joint — raises concern about cumulative effects on cartilage matrix integrity, so dosing is kept to a minimum while other options are considered.

Hyaluronic acid (HA) supplements the joint's natural lubricating fluid rather than suppressing inflammation. Relief tends to build over weeks rather than days. Combined regimens — double-dose HA with chondroitin sulphate — have shown maximum pain reduction at three months in stage III post-traumatic OA, and some structural rationale accompanies the symptomatic benefit.

Orthobiologics — including platelet-rich plasma (PRP), microfragmented adipose tissue (mFAT), and bone marrow aspirate concentrate (BMAC) — are increasingly used during this window. Published evidence supports symptom improvement across post-traumatic knee OA populations, but confirmed structural preservation has not been established at this stage of disease. The evidence base is growing rather than settled.

Longer-acting injectables such as polyacrylamide hydrogel (for example, Arthrosamid®) work by integrating into the synovial lining to provide cushioning, a mechanism distinct from viscosupplementation or biologics. Evidence for delaying arthroplasty remains promising but preliminary.

Timing any injection around planned surgery is not a minor detail — the relationship between pre-operative injection and infection risk carries a specific clinical threshold that warrants its own consideration.

The 3-month rule: injection timing before knee replacement

The most common practical question at this stage is whether an intra-articular injection is still safe if a knee replacement is being considered. The short answer is yes — provided the timing is managed.

A meta-analysis of eight studies covering more than 200,000 TKA patients found that intra-articular injections administered within three months of surgery increase the risk of periprosthetic joint infection (RR 1.26; 95% CI 1.18–1.35). The risk is not evenly distributed within that window: the sharpest spike occurs within two weeks of the operation. Beyond the three-month mark, the same evidence shows no statistically significant elevation in infection risk. This threshold now forms the standard planning boundary used by orthopaedic surgeons before scheduling TKA.

Both corticosteroid and hyaluronic acid carry this risk within the window; the meta-analysis did not demonstrate meaningful difference between agent types. Whether orthobiologics such as PRP or polyacrylamide hydrogel carry a lower pre-TKA infection risk than corticosteroid has not been established by direct comparative evidence — this remains an open question in the literature.

The practical implication is straightforward: this is a planning rule, not a warning against injections altogether. Patients who have no confirmed surgery date face no constraint from it. When a TKA date is eventually set, the three-month boundary becomes part of the surgical plan — meaning that for most patients, the injection window and the arthroplasty pathway can coexist without conflict.

When knee replacement becomes the realistic next step

For patients who do progress towards joint replacement, an ACLR history introduces surgical considerations absent from primary TKA. Prior bone tunnels may need grafting, anatomical changes alter landmark recognition, and residual ligamentous laxity can influence implant selection — all of which increase operative time and technical demand compared with a first-time knee replacement.

Unicompartmental replacement carries a specific caveat

Where OA has settled predominantly in one compartment, a partial (unicompartmental) replacement might seem proportionate. The survivorship data after prior ACLR complicate this, however. Nine-year reoperation-free survival for medial mobile-bearing UKA falls to 81.2% in patients with a previous reconstruction, versus 92.1% in matched controls, with bearing dislocation risk eight times higher. This does not rule out UKA in every case, but it is information a patient should have before settling on partial over total replacement.

Weight management as a co-management target

Body weight is one of the few modifiable variables with direct, quantified impact on the arthroplasty pathway. In a nationwide cohort of 56,734 patients, those who were overweight (BMI 25–29.9) at the time of ACLR faced a hazard ratio of 1.93 for subsequently requiring HTO or TKA — nearly double the risk of normal-weight patients. This gives concrete clinical weight to diet, supervised exercise, and metabolic health while still in the injection window: not peripheral suggestions, but factors embedded in the outcome data.

What moves the decision forward

Imaging findings alone do not determine when replacement is appropriate. Persistent pain that resists conservative and injection management, and that limits everyday function, is the primary driver. For post-ACLR patients specifically, a practical clinical checkpoint is whether a second cycle of injection management has failed — and whether compartment distribution, ligamentous adequacy, and weight trajectory have been reviewed before fixing a surgical date. A scan showing advanced OA is one input; the inability to manage daily function otherwise is the threshold.

1. [1] Clinical Outcomes and Osteoarthritis at Very Long-term Follow-up After ACL Reconstruction: A Systematic Review and Meta-analysis. (2022). https://doi.org/10.1177/23259671211062238 https://doi.org/10.1177/23259671211062238
2. [2] Radiographic Incidence of Knee Osteoarthritis After Isolated ACL Reconstruction Versus Combined ACL and ALL Reconstruction: A Prospective Matched Study From the SANTI Study Group. (2023). https://doi.org/10.1177/03635465231168899 https://doi.org/10.1177/03635465231168899
3. [3] How is the Rate of Total Knee Arthroplasty Influenced by ACL Injury Treated by ACL Reconstruction Versus Non-Operative Treatment and How Does Prior ACL Reconstruction Compromise Outcomes: A Systematic Review. (2025). https://doi.org/10.17161/kjm.vol18.24437 https://doi.org/10.17161/kjm.vol18.24437
4. [4] Longitudinal Changes in Medial Meniscal Extrusion After ACL Injury and Reconstruction and Its Relationship With Cartilage Degeneration Assessed Using MRI-Based T1ρ and T2 Analysis. (2025). https://doi.org/10.1177/03635465241305734 https://doi.org/10.1177/03635465241305734
5. [5] Relationship Between Revision Rate, Osteoarthritis, and Obesity for ACL Reconstruction: A Nationwide Retrospective Cohort Study. (2024). https://doi.org/10.1177/23259671241266597 https://doi.org/10.1177/23259671241266597
6. [6] Medial mobile-bearing unicompartmental knee arthroplasty following anterior cruciate ligament reconstruction is associated with an increased revision risk compared to controls. (2025). https://doi.org/10.1002/ksa.70185 https://doi.org/10.1002/ksa.70185
7. [7] Patellofemoral joint loading and early osteoarthritis after ACL reconstruction. (2023). https://doi.org/10.1002/jor.25504 https://doi.org/10.1002/jor.25504
8. [8] Conversion Total Knee Arthroplasty. (2021). https://doi.org/10.2106/JBJS.RVW.20.00198 https://doi.org/10.2106/JBJS.RVW.20.00198